Stay updated with breaking news from Noacs doacs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The phase 3 OCEANIC-AF trial of the factor XI inhibitor asundexian (Bayer) has been stopped early owing to inferior efficacy vs apixaban in preventing stroke and systemic embolism in patients with AF. ....